Clinical trial Recruiting at 1 site Interventional Ages 18 to 85

Mobile health intervention for managing hypertension in ICH survivors

Official title: MOBILE Health Intervention in IntraCerebral Hemorrhage Survivors

Run by The University of Hong Kong · NCT05830305 · Data updated 2026-11-12

This study is testing a mobile health program to see if it helps people who have survived a brain bleed manage their high blood pressure better than regular doctor visits.

More Hypertension trials

Quick facts

Study typeInterventional
Ages18 Years to 85 Years
SexAll
Enrollment140 (estimated)
SponsorThe University of Hong Kong
Academic / other
Locations1 site (Hong Kong)
StatusRecruiting
StartedOctober 1, 2023
Main results expectedDecember 31, 2026
Study endsMarch 31, 2027
Registry record updatedJanuary 6, 2026
Trial IDNCT05830305 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older who have been diagnosed with primary intracerebral hemorrhage and have a modified Rankin Scale score of 4 or less upon discharge.

Probably not a fit

Patients who may not benefit include those with severe comorbid conditions, significant cognitive impairments, or those unable to access or use the WeRISE app for monitoring.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized controlled trial evaluates the effectiveness and safety of a mobile health intervention aimed at managing hypertension in survivors of intracerebral hemorrhage (ICH). A total of 140 participants will be divided into two groups: one receiving the mobile health intervention, which includes daily blood pressure monitoring through the WeRISE app and regular follow-up calls for medication adjustments, and the other receiving standard care from their physicians. The study will track participants for 26 weeks to assess the control of hypertension at specified intervals. The intervention emphasizes education on hypertension management and lifestyle modifications, such as the DASH diet.

Why it matters

Potential benefit: If successful, this intervention could significantly improve blood pressure control in ICH survivors, potentially reducing the risk of further complications.

How similar studies have gone: Other studies have shown promise in using mobile health interventions for chronic disease management, suggesting potential success for this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Primary ICH Diagnosis
* Age ≥ 18 years
* Discharge Modified Rankin Scale of ≤4

Exclusion Criteria:

* Expected life expectancy of \<1 year
* Patient or caregiver does not have access to WeRISE App.
* Patient or caregiver does not know how to use WeRISE App .
* Inability to perform home BP monitoring
* Inability to participate in follow-up activity
* Contraindication for intensive and rapid lowering of blood pressure (Known \>70% cerebral vascular stenosis; History of fall, dizziness or syncope due to hypotension; Any other medical condition that is deemed contraindicated for low blood pressure
* Bleeding tendency (Platelet count \< 75 x 10\^9/L; Known coagulation disorder)
* Severe renal impairment (Estimated glomerular filtration rate using CKD-EPI formula \<30 ml/min/1.73m2)
* Severe liver impairment (Child-Pugh C cirrhosis)
* Known contraindication or allergy to two or more anti-hypertensive classes

Where it's running

  • Queen Mary Hospital
    Hong Kong, Hong Kong
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.